Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 86.91$. Average daily volumn in 3 months 2.48M. Market cap 187.45B



Stock symbol : NVS. Exchange : NYSE. Currency : USD
Lastest price : 84.53$. Total volume : 2.81M. Market state PRE
Click reload if you want to check the lastest price on market!!!

Novartis AG (NVS)
Last Price
84.53$
Change
-0.24
Volume
2.81M

Previous Close84.77
Open84.36
Day Range83.73-84.98
Bid82.93 x 800
Ask83.24 x 800
Volume2.81M
Average Volume2.48M
Market Cap187.45B
Beta0.48
52 Week Range79.09-95.17
Trailing P/E7.89
Foward P/E12.47
Dividend (Yield %)3.93%
Ex-Dividend Date2022-03-08



Financial Details


According to Novartis AG's financial reports the company's revenue in 2021 were 52.88B an increase( +6.12%) over the years 2020 revenue that were of 49.9B. In 2021 the company's total earnings were 24.02B while total earnings in 2020 were 8.07B( +200%).


Loading ...



Organization

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form me... dicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Market Cap:
187.45B
Revenue:
52.88B
Total Assets:
131.79B
Total Cash:
12.41B


News about "Novartis AG"

spire-wealth-management-has-660000-stock-position-in-novartis-ag-nysenvs-image

Spire Wealth Management Has $660,000 Stock Position in Novartis AG (NYSE:NVS)

Source from : Defense World - 9 hours ago

Spire Wealth Management lowered its stake in shares of Novartis AG (NYSE:NVS โ€“ Get Rating) by 30.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 7,519 shares of the companyโ€™s ...See details»


novartis-leaning-toward-spinoff-of-25-billion-generics-arm-image

Novartis Leaning Toward Spinoff of $25 Billion Generics Arm

Source from : YAHOO!Finance - 1 days ago

Novartis AG is leaning toward a spinoff of its generic-drug unit, as a challenging environment for leveraged buyouts makes a potential sale to private equity more difficult, people familiar with the ...See details»


novartis-weighs-listing-of-25b-generic-unit-bloomberg-image

Novartis weighs listing of $25B generic unit โ€“ Bloomberg

Source from : Seeking Alpha - 1 days ago

Swiss drugmaker, Novartis AG (NVS) (NVSEF) is said to be leaning towards a potential spinoff of its Sandoz business and a separate listing of the $25B generics drug unit ...See details»


novartis-tislelizumab-extends-overall-survival-in-late-stage-esophageal-cancer-study-image

Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study

Source from : YAHOO!Finance - 1 days ago

Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal ...See details»


385-shares-in-novartis-ag-nysenvs-purchased-by-dedora-capital-inc-image

385 Shares in Novartis AG (NYSE:NVS) Purchased by DeDora Capital Inc.

Source from : ETF Daily News - 4 days ago

DeDora Capital Inc. acquired a new stake in Novartis AG (NYSE:NVS โ€“ Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 385 shares of ...See details»


dedora-capital-inc-takes-position-in-novartis-ag-nysenvs-image

DeDora Capital Inc. Takes Position in Novartis AG (NYSE:NVS)

Source from : Defense World - 4 days ago

DeDora Capital Inc. bought a new stake in Novartis AG (NYSE:NVS โ€“ Get Rating) in the first quarter, HoldingsChannel.com reports. The firm bought 385 shares of the companyโ€™s stock, valued at ...See details»


Novartis to cut up to 8,000 jobs globally

Source from : Reuters - 3 days ago

An employee smokes a cigarette beside the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011. REUTERS/Arnd Wiegmann ...See details»


novartis-loses-in-patent-appeal-over-multiple-sclerosis-drug-image

Novartis loses in patent appeal over multiple sclerosis drug

Source from : Reuters - 9 days ago

A U.S. appeals court on Tuesday ruled that a patent related to Swiss drugmaker Novartis AG's blockbuster multiple sclerosis drug Gilenya was invalid, potentially paving the way for introduction of a ...See details»


novartis-ag-nysenvs-short-interest-update-image

Novartis AG (NYSE:NVS) Short Interest Update

Source from : ETF Daily News - 13 days ago

Novartis AG (NYSE:NVS โ€“ Get Rating) was the target of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 5,970,000 shares, a drop of 15.7% ...See details»


novartis-nvs-gets-positive-chmp-opinion-for-scemblix-in-cml-image

Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML

Source from : Nasdaq - 4 days ago

Novartis AG NVS announced that the European Medicines Agencyโ€™s Committee for Medicinal Products for Human Use (โ€œCHMPโ€) has rendered a positive opinion on, and recommended granting marketing ...See details»


SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS

Source from : Associated Press - 7 days ago

Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (โ€œNovartisโ€ or the โ€œCompanyโ€) (NYSE: NVS). Such inv ...See details»


pearl-huang-to-lead-novartis-partnered-startup-image

Pearl Huang to lead Novartis-partnered startup

Source from : The Business Journals - 3 days ago

Former Roche and Cygnal Therapeutics executive Pearl Huang is now the CEO and 12th employee of a tiny startup called Dunad Therapeutics.See details»


Bragar Eagel & Squire, P.C. Is Investigating Novartis, Medallion, RBB, and Agrify and Encourages Investors to Contact the Firm

Source from : Associated Press - 6 days ago

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS), Medallion Financial Corp. (NASDAQ: MFIN), RBB ...See details»


Novartis Pharma AG: Novartis receives positive CHMP opinion for Scemblix, a novel treatment for adult patients with chronic myeloid leukemia

Source from : Finanznachrichten - 7 days ago

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least ...See details»